NASDAQ:DMRA Damora Therapeutics, Inc. Common Stock Q4 2024 Earnings Report $22.59 -0.19 (-0.83%) As of 09/18/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Damora Therapeutics, Inc. Common Stock EPS ResultsActual EPS-$5.22Consensus EPS -$3.12Beat/MissMissed by -$2.10One Year Ago EPSN/ADamora Therapeutics, Inc. Common Stock Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADamora Therapeutics, Inc. Common Stock Announcement DetailsQuarterQ4 2024Date3/19/2025TimeBefore Market OpensConference Call DateTuesday, March 18, 2025Conference Call Time7:00PM ETConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Damora Therapeutics, Inc. Common Stock Earnings HeadlinesDamora Therapeutics: Potential Payday Is A Long Way OffSeptember 15, 2026 | seekingalpha.comDAMORA THERAPEUTICS INCSeptember 12, 2026 | finanznachrichten.deYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Damora Therapeutics Grants Inducement Awards To Three New EmployeesSeptember 3, 2026 | rttnews.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comDamora Therapeutics: Competition Validates The Target While Its Portfolio Creates The UpsideAugust 12, 2026 | seekingalpha.comSee More Damora Therapeutics, Inc. Common Stock Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Damora Therapeutics, Inc. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Damora Therapeutics, Inc. Common Stock and other key companies, straight to your email. Email Address About Damora Therapeutics, Inc. Common StockGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.View Damora Therapeutics, Inc. Common Stock ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
